Axio BioPharma began with Forge: a biologics lab built around the belief that AI could meaningfully change how bioprocess development works.
Biologics development generates valuable knowledge, but that knowledge breaks down as it moves across systems, teams, and organizations.
We started Axio with a practical conviction: AI would only matter in this space if it was grounded in real execution.
Forge gave us a direct view into:
It also made the opportunity clear:
a better system could emerge from the workflows themselves.
Forge is our foundation. A lab where real work, real data, and real constraints shaped our perspective.
That experience led to a broader conclusion:
Process knowledge does not scale with the science. It fragments as work moves across systems and organizations.
That is what gave birth to Lattice.
Lattice is the system we are developing in response — designed to help process understanding move more effectively across sites, partners, and programs.
Forge is the origin.
Lattice is the broader future it revealed.
We build from how teams actually operate, not how systems are ideally designed.
Our perspective comes from doing the work, not observing it.
Biologics development spans sites and partners. The system has to reflect that.
Led by industry veterans with experience across biologics, commercialization, bioinformatics, and AI.
Justin Byers
Founder, CEO
Biopharma PD and commercial leader focused on building biomanufacturing services from the ground up.
Brian Staats
Co-founder, CTO
Technology leader specializing in bioinformatics with 20+ years in modeling, data science, and engineering.
Dave Watrous
Chief Commercial Officer
Senior executive with over 20 years driving global growth and operational excellence across bioprocessing, SaaS, and CDMO organizations.
A powerhouse advisory team with deep expertise in biologics, R&D, and life sciences leadership.
Graham Brearley, PhD
Advisor
A BioPharma expert with 30+ years of experience in biologics development, operations leadership, and business growth through acquisitions, divestitures, and due diligence.
Greg Bleck, PhD
Advisor
Former VP of R&D at Catalent, co-founded Gala Design; developed technologies used in 20+ approved biopharmaceuticals, contributed to 175+ clinical trial molecules, and holds 20+ patents.
Patrick Haffey
Advisor
Life sciences executive with 20 years of experience building, qualifying, and commercializing new biopharma manufacturing businesses in the US and abroad.
We will get back to you immediately.
